X

Vous n'êtes pas connecté

Maroc Maroc - DRUGS.COM - New Drug Approvals - 17/12/2024 06:12

FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara

JERSEY CITY, N.J., Dec. 17, 2024 -- Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in...

Articles similaires

Sorry! Image not available at this time

FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications

drugs.com - 03/Jan 16:01

FRIDAY, Jan. 3, 2025 -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for...

Sorry! Image not available at this time

FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications

drugs.com - 03/Jan 16:01

FRIDAY, Jan. 3, 2025 -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for...

Sorry! Image not available at this time

STEQEYMA (ustekinumab) injection, solution [CELLTRION Inc.]

nlm.nih.gov - 30/12/2024 05:00

Updated Date: Mon, 30 Dec 2024 00:00:00 EST

Sorry! Image not available at this time

STEQEYMA (ustekinumab) injection, solution [CELLTRION Inc.]

nlm.nih.gov - 30/12/2024 05:00

Updated Date: Mon, 30 Dec 2024 00:00:00 EST

Sorry! Image not available at this time

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

drugs.com - 08/Jan 22:01

TITUSVILLE, N.J., January 8, 2025 -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted...

Sorry! Image not available at this time

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

drugs.com - 08/Jan 22:01

TITUSVILLE, N.J., January 8, 2025 -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted...

Sorry! Image not available at this time

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

drugs.com - 30/12/2024 23:12

BOSTON--(BUSINESS WIRE)--Dec. 30, 2024-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for...

Sorry! Image not available at this time

FDA Approves Gemtesa for Overactive Bladder in Men With BPH

drugs.com - 02/Jan 22:39

THURSDAY, Jan. 2, 2025 -- Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB)...

Sorry! Image not available at this time

FDA approves first drug for sleep apnea treatment

knowridge.com - 30/12/2024 11:04

The U.S. Food and Drug Administration (FDA) has approved Zepbound, a prescription weight-loss medication, as the first drug specifically for treating...

Sorry! Image not available at this time

Monthly News Roundup - December 2024

drugs.com - 31/12/2024 22:12

FDA Approves Zepbound as the First Prescription Drug for Obstructive Sleep Apnea in Adults with Obesity On December 20, 2024, the U.S. Food and Drug...